ID: MRFR/HC/6899-HCR | February 2021 | Region: Global | 100 pages
Global Non-Invasive Prenatal Testing (NIPT) Market is expected to cross USD 8,217.53 Million by 2025 at a CAGR of 12.8%
NIPT is the testing procedure done during the pregnancy period to monitor the fetal growth and related diagnosis. Annually it is predicted that around 21 million girls aged 15 to 19 years give birth in developing regions around the globe.
Thus, it is among the reasons why NIPT is needed for safe delivery of the baby.
The birth rate is expected to increase during the forecast period.
Rising cases of premature pregnancy in developing and underdeveloped countries.
By Product Type
The global NIPT market based on product type is broadly segmented into devices, consumables, and others.
The global NIPT market based on technique is segmented into biochemical screening tests and ultrasound detection.
Frequently Asked Questions (FAQ) :
The global non-invasive prenatal testing (NIPT) market is projected to reach a valuation of USD 8,217.53 MN by 2025.
The global non-invasive prenatal testing (NIPT) market is projected to grow at approximately 12.8% CAGR during forecast period (2019-2025).
Adoption of unhealthy lifestyle habits during pregnancy.
North America holds the largest share in the global non-invasive prenatal testing (NIPT) market, followed by Europe and the Asia Pacific, respectively.
Thermo Fisher Scientific, Inc. (US), Illumina, Inc. (US), General Electric Company [GE Healthcare] (US), Agilent Technologies, Inc. (US), Perkinelmer, Inc. (US), Beijing Genomics Institute (China), Tarsa Therapeutics, Inc. (US), Hoffman-La Roche Ltd. (Switzerland), PhytoHealth Corporation (Taiwan), Natera, Inc. (US), Laboratory Corporation of America Holdings (US), Centogene Holding AG (Germany), and Yourgene Health (UK), are some of the major players operating in the non-invasive prenatal testing (NIPT) market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.